Spiral is navigating the intersection of big data and AI —leading the way in ethical clinical trial design. In the rapidly evolving healthcare landscape, we prioritise ethical governance, where data, compliance, and human-centred trials converge.

In the fast-paced world of software, adaptability is key. Our Spinnaker software is always evolving to stay innovative. Because of this, we're now rebuilding a project from the ground up, seizing the chance to harness Blazor, a cutting-edge web development framework, as we navigate changes in the Core Protocol.

Cain Harland, one of the minds behind Spiral's Spinnaker software, is not your typical Developer. His unique journey blends his passion for problem-solving with a commitment to advancing medical knowledge and improving patient outcomes.

After an invigorating week at the ACTA International Clinical Trials Symposium in Melbourne, it's time to pause and reflect on an event that truly exemplified the theme ‘Changing the landscape of clinical trials.’

Diane Mackle, an experienced ICU nurse and now Project Manager of the trial, plays a pivotal role here in New Zealand managing the Mega-ROX trial and its coordination with the Spiral team and Spinnaker software.

The TAME trial, a phase III clinical trial, aimed to investigate whether targeted therapeutic mild hypercapnia (TTMH) could improve neurological outcomes at 6 months for resuscitated cardiac arrest patients in comparison to standard care (targeted normocapnia). This study holds significant importance in exploring potential advancements in post-cardiac arrest treatment strategies.

The world of REMAP-CAP is constantly evolving, here’s what’s new!

REMAP-CAP, a groundbreaking trial that has most recently been primarily focused on finding treatments for COVID-19, has now been selected by the National Institute for Healthcare and Research to evaluate therapeutic interventions for influenza.

New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.

We have another important milestone to celebrate! On the 17th of February 2023, the SNAP (Staphylococcus Aureus Network Adaptive Platform) Trial reached its one-year anniversary.

Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.

New results are in for the ASCOT Trial (Australasian Covid-19 Trial), another study in Spiral’s manifest of platform trials. This platform trial was set up to evaluate 3 different treatment approaches for effectiveness against COVID-19. Each of these approaches is called a 'domain'. The findings from the anticoagulation domain have recently been published in the New England Journal of Medicine Evidence.

After two years of online meetings, attending the Australian Clinical Trials Alliance Annual Science meeting in Adelaide in November felt fantastic. It was a whirlwind of activity, new technology, connections, learning, and, importantly, an excellent opportunity to connect with industry peers.